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Sumnuary High levels of IL-6 were found in 50% of 114 patients with pnrmary ovarian cancer. IL-6
sensitivity was lower than that of CA 125. and the combination of both assays did not increase the sensitivity
of CA 125 alone. However, elevated IL-6 serum levels were correlated with a poor prognosis since patients
with low IL-6 levels had a better survival than patients with high IL-6 levels (P = 0.0009). Multivariate
analysis revealed that IL-6 positivity has an independent value.
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Recent evidence has shown that IL-6. a multifunctional
cytokine that regulates immune responses. acute-phase reac-
tions and haematopoiesis. stimulates the proliferation of
ovarian cancer cells in culture (Wu et al.. 1992). Moreover. it
has been reported (Watson et al.. 1990: Berek et al.. 1991)
that ascites of ovarian cancer patients contain high levels of
IL-6 which correlate with disease status. Our previous report
demonstrated that high serum IL-6 levels are a unique
feature of ovarian cancer as compared with other gynae-
cological malignancies (Scambia et al.. 1994) and that.
although IL-6 is less sensitive than CA 125 as a tumour
marker for ovarian cancer. the production of IL-6 may be
related to tumour aggressiveness.
The present study investigated the prognostic significance
of serum IL-6 levels in 114 primary ovarian cancer patients.
The correlation between IL-6 and the IL-6 soluble receptor
(IL-6R) was also investigated.
Patients and methods
A total of 114 patients with malignant ovarian tumours
admitted to the Department of Gynecology of the Catholic
University or to the Department of Gynecology of the
University of Pisa from June 1987 to December 1993 were
enrolled in the study. Seventy-four healthy women aged
22-68 years were included as controls. The World Health
Organization (WHO), method of histological typing of
ovarian tumour was adopted (Serov et al., 1973).
After surgery patients received cisplatin-containing
regimens (Benedetti Panici et al., 1993). Patients who initially
had only an explorative laparotomy underwent a second
laparotomy after chemotherapy, and a second cytoreduction
was attempted. Venous blood samples for marker determina-
tions were separated by centrifugation and aliquots were
stored at - 20°C until assay. IL-6 and IL-6R assays were
performed using commercially available specific enzymatic
immunoassays (RandD Systems Minneapolis, MN, USA).
The detection threshold for IL-6 evaluation was 0.3 pg ml-'.
The intra-assay variability for IL-6 and IL-6R analyses was
5-20% and 5-10% respectively. Since >95% of normal
controls exhibited IL-6 serum levels within the range
1.9-6 pg ml-', 6 pg ml- ' was used as the cut-off value. Nor-
mal control values of IL-6R ranged between 14.9 and
46.4 ng ml-' (mean value 26.5 ng ml-'). CA 125 was
measured using a commercially available kit (CIS, Com-
pagnie ORIS Industrie SA) and the upper limit of CA 125
for normal controls was 35 U ml-' (Scambia et al.. 1990).
The chi-square and Fisher's exact test were used to analvse
the relationship between IL-6 serum values and tumour
characteristics. All medians and life tables were computed
using the product-limit estimate by Kaplan and Meier (1958).
and the curves were examined by the log-rank test (Mantel.
1966). Multivariate analysis was performed with BMDP
statistical software (Dixon, 1981). A backward stepwise pro-
cedure was used to identify the major prognostic factors.
Survival time was calculated from the date of diagnosis to
the date of death.
Results
Table I shows the comparison of IL-6 distribution and
positivity of IL-6 and CA 125 according to clinocopatho-
logical parameters. IL-6 positivity was not significantly
related to stage, histology, grading or presence of ascites.
However, the percentage of IL-6 positivity was significantly
higher in patients with post-operative residual tumour
> 2 cm as compared with patients with residual tumour
( 2 cm (P = 0.02). Although no linear correlation between
IL-6 and CA 125 levels was found, the overall sensitivity was
only slightly increased by the combination of IL-6 and CA
125. Ninety-two per cent of the serum samples showed a
positive reaction in at least one test as compared with 87%
for CA-125 alone (data not shown).
Soluble IL-6R was also measured in 44 patients. Receptor
levels were significantly increased as compared with normal
controls (mean ± s.e.m 127 ± 1.1 range, 109.7-153.1. vs
26.5 ± 1.04, 14.9-43.4). No correlation between IL-6R and
IL-6 serum levels was found (P = 0.27. P = 0.15). Moreover.
IL-6R was not related to any clinicopathological characteris-
tics (data not shown).
Survival analysis of the overall patient population showed
a shorter survival for patients with high IL-6 levels as com-
pared with those patients presenting normal or low IL-6
values (P = 0.001). However, in order to avoid possible bias
owing to the inclusion of patients with early-stage disease,
survival analysis was limited to patients with stage II. III and
IV ovarian cancer. Follow-up data were available for 83 of
these patients. and death occurred in 38 cases. Figure 1 a
shows the cumulative percentage survival as related to serum
IL-6 status at initial diagnosis. A highly significant correla-
tion between patients with low IL-6 levels and a longer
survival compared with patients with high IL-6 levels
(P = 0.0009) was observed. Median survival was 21 months
for patients with high IL-6 serum levels as compared with 51
months for patients with low IL-6 values. Figure lb shows
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Table I IL-6 serwm levels and positivity of IL-6 and CA 125 in ovarian cancer in
relation to different clnicopathological parameters
IL-6 IL-6 CA 125
No. of sera Median (range) >6pgml-' >35Uml-'
tested (pg ml-') No. (%) No. (%)
Total 114 5.8 (0.3-660) 57 (50) 99 (87)
Stage
I 19 1.5 (0.3-20) 7 (37) 10 (53)
II 8 5 (0.4-90) 3 (37) 7 (87)
III 62 6.9 (0.3-660) 33 (53) 57 (92)
IV 25 7 (0.7-180) 14 (56) 25 (100)
Histology
Serous 80 7 (0.3-660) 43 (54) 72 (90)
Mucinous 9 1.5 (0.4-55) 2 (22) 7 (78)
Endometrioid 6 4.4 (0.4-20) 2 (33) 5 (83)
Undifferentiated 8 4.5 (0.4-26) 4 (50) 8 (100)
Others 11 7.7 (0.4-55) 6 (54) 7 (64)
Grading
1 14 9.8 (0.4-120) 7 (50) 11 (78)
2 30 4.3 (0.3-110) 11 (37) 24 (80)
3 62 7 (0.3-660) 35 (56) 56 (90)
Ascitesa
No 41 4.9 (0.3-660) 20 (49) 37 (90)
Yes 46 8.9 (0.4-280) 27 (59) 44 (96)
Residual tumour after surgery'
2cm 48 4.4 (0.3-660) 21 (44)* 45 (94)
>2cm 39 8.3 (0.4-280) 26 (67) 36 (92)
YOnly patients with stage III and IV disease are considered. *P = 0.02.
Table II Univariate and multivanrate analysis of survival in stage





II-II 127 0.0169 0.0023
Residual -tumour
after surgery
,<2cm 51 007070 >2cm 20 0.7 0.772
Grading
3-2 22 0.038 0.15
Pretreatment IL-6
<6pgml-' 21 0.009 0.0081 6 gml'2
Fgwe I a. Overall survival in patients with stage II, III or IV
ovarian cancer in relation to IL-6 serum levels. b, Overall survival
in patients with stage II, III or IV ovarian cancer with complete
and partial response to chemotherapy in relation to IL-6 serun
levels.
the overall survival of patients with stage II, III or IV
ovarian cancer with a complete or partial response to
chemotherapy. In this case there was also a statistically
significant difference between patients with high IL-6 levels
and a poor prognosis and those with low IL-6 and a better
prognosis (P = 0.0227). Univariate analysis (Table II)
showed that stage IV disease, post-operative residual tumour
diameter greater than 2 cm, grading and high pretreatment
IL-6 serum levels were significantly correlated with a
shortened survival. Multivariate analysis revealed that only
FIGO stage and pretreatment IL-6 levels were significantly
correlated with a high risk of death.
Prognostic characterisation of patients with advanced ovar-
ian cancer is still inadequate. Therefore, identification of
variables correlating with tumour aggressiveness would con-
tribute to the selection of therapy for individual patients.
Our results show that elevated IL-6 serum levels in patients
with primary epithelial ovarian cancer correlate with poor
prognosis. Multivariate analysis showed that the association
of high IL-6 levels with poor survival was independent of the
other known prognostic factors such as stage and residual
disease.
These results are consistent with previous data reported by
Reibnegger et al. (1992) showing an association between IL-6
and disease progress in multiple myeloma. High serum IL-6
is also an adverse prognostic factor in renal cancer (Blay et
al., 1992) and glioblastoma (Van Meir et al., 1990). Several
observations support the hypothesis that IL-6 expression is
related to tumour aggressiveness: (i) IL-6 is a growth factor
for ovarian and renal carcinoma cells (Miki et al., 1989; Wu
et al., 1992); (ii) renal cancer cells express IL-6 receptor
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function in an autocrine fashion; and (iii) Tamm et al. (1989)
showed that exogenous IL-6 increases the motility and de-
creases adherence of the breast carcinoma cell lines T47D
and ZR75-1. suggesting that in vivo IL-6 may promote
tumour metastasis and invasiveness. Alternatively, IL-6 could
exert an adverse effect through a modulation of the anti-
tumour response. Although in vitro IL-6 enhances the func-
tions of cytotoxic T lymphocytes and natural killer cells and
svnergises with IL-2 to increase the cytotoxic activity of
peripheral blood T lymphocytes (Okada et al.. 1988), high
concentrations of IL-6 inhibit the immune tumour response
in a murine model (Tanner and Tosado, 1991). In view of the
high concentration of IL-6 found in ascites of ovarian cancer
patients. this cytokine may play a similar role in this disease
(Watson et al.. 1990).
In our series. increased IL-6 serum levels were accom-
panied by augmented IL-6R concentration. The regulation in
vivo of the shedding of soluble IL-6Rs, the function and the
significance of these soluble receptors in biological fluids are
not currently understood. It has been suggested, however.
that pathological conditions involving elevated levels of IL-6
might also be associated with increased production of soluble
IL-6Rs (Honda et al.. 1992). Accordingly, ovarian cancer
patients exhibited increased serum levels of both IL-6 and
soluble IL-6Rs.
The present report on a larger population confirms our
previous finding that IL-6 is not a useful tumour marker for
ovarian cancer. The sensitivity of IL-6 is lower than that of
CA 125. Furthermore, combined IL-6 and CA 125 only
slightly increased the overall sensitivity as compared with CA
125 alone.
This study, together with the in vitro results indicating that
ovarian cancer cell proliferation and tumour angiogenesis are
affected by IL-6 (Motro et al., 1990), suggests new thera-
peutic strategies based on IL-6 interference by antisense
oligonucleotides or monoclonal antibodies. In this regard,
recent reports have shown that addition in culture of anti-IL-
6 antibody and/or IL-6 mRNA antisense oligonucleotides
inhibits the proliferation of carcinoma cell lines (Miki et al.,
1989; Watson et al., 1993).
In conclusion, data from the present study suggest that the
assessment of serum IL-6 at the time of initial surgery may
allow the identification of a subset of patients with a parti-
cularly poor prognosis. This aspect should be investigated in
a larger clinical trial including other biological parameters in
the multivariate analysis.
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